Presentation on theme: "Chloe Walsh ACF infectious diseases MSc by thesis (part time) Supervisors: Dr Gavin Barlow, Dr Victoria Allgar."— Presentation transcript:
Chloe Walsh ACF infectious diseases MSc by thesis (part time) Supervisors: Dr Gavin Barlow, Dr Victoria Allgar
What is Invasive Pneumococcal Disease? Pneumococcus is a gram positive bacterium that colonises the upper respiratory tract. Can become pathogenic Invasive Pneumococcal disease (IPD) is diagnosed when Pneumococcus is isolated from a normally sterile site.
Why is IPD important? Around 2 million deaths are attributed to Pneumococcus globally per annum Local study of IPD (Elston et al) found that 21.6% of patients died within 30 days of diagnosis 36.8% of patients died within one year of diagnosis. Overall incidence of IPD of 11.8/ in 2002, increasing to 16.4/ by 2009
IPD and Mortality Traditionally considered an acute illness Both pneumonia and sepsis have been associated with longer term mortality Determinants of this poorer long term outcome are not fully understood
Serotypes Over 90 serotypes based on polysaccharide capsule “Invasive” versus “colonising” “Colonising” serotypes associated with poorer outcomes Capsule is target for vaccination
Role of serotype Meta-analysis has shown 1, 7F and 8 to be associated with better outcomes (“low severity”) 3, 6A, 6B, 9N and 19F are (“high severity”) Although relationship to acute deaths has been studied, whether serotypes influence longer term mortality has not been established
Methods Retrospective cohort All patients admitted to Hull Royal Infirmary or Castle Hill with IPD between 2002 and 2009 identified Serotype recorded where available and classified as “low severity”, “high severity” or “other” Demographic data also collected (sex, age at time of sample and index of multiple deprivation (IMD) score)
Results N=553 Mean age % female Mean IMD 31.9 (range ) Overall mortality at 30 days, 1 year and 2 years respectively 22.9%, 36.9% and 42.4% respectively
Results Mortality in patients with lower risk serotypes (1, 7F and 8) (n=123) was lower than with higher risk serotypes (3, 6a, 6B, 9N and 19F) (n=75); 11.4% versus 21.3% at 30 days (p =0.012). At 1 and 2 years p<0.001 Increasing age (p<0.001) and male sex (p=0.003) also associated with increased mortality at 2 years.
Mortality rate at 30 days, 1 year and 2 years by Serotype Group
Cumulative survival by Serotype Group
Conclusions IPD is associated with increased mortality up to 2 years following infection Infection with a “high severity” serotype is associated with worse outcome No evidence that infection with “low severity” serotype is associated with increased long term mortality
Discussion Possible that patients who have infections caused by “high severity” serotypes have a lower barrier to infection due to underlying co-morbid illness Ongoing work to further establish factors associated with poor long term outcomes Important to understand the role of serotype for future vaccine development